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A
disease whose reputation is often worse than its reality, hepatitis C is usually benign. Most infected individuals do not 
experience symptoms requiring treatment, and roughly half of those treated will become free of detectable virus for an
extended, perhaps permanent, period. Moreover, a growing body of data suggests that drug users can attain successful treat-
ment outcomes, even when not completely abstinent. Addiction professionals belong in the forefront of prevention and manage-
ment of this disease. We can assist our patients by helping them stabilize their lifestyles, correcting misperceptions about the 
disease, teaching prevention and health maintenance, promoting access to diagnosis and treatment, monitoring for treatment
side effects, and providing encouragement to remain in treatment.
Hepatitis C for Addiction Professionals
herapy [for hepatitis C] has been successful even when the patients
have not abstained from continued [injection] drug or alcohol use
or are on daily methadone. Thus, it is recommended that active injec-
tion drug use in and of itself not be used to exclude such patients from antiviral
therapy.” So concludes the section entitled “Active Injection Drug Users” in the
2002 National Institutes of Health Consensus Development Conference state-
ment on the management of hepatitis C (National Institutes of Health, 2002).
Despite this authoritative guideline, most addiction specialists encounter dif-
ficulties in referring patients for hepatitis C viral testing, liver biopsy, or treatment.
Indeed, addiction specialists struggle to provide access to basic services such as
hepatitis C virus (HCV) screening and hepatitis A and B vaccinations. The dis-
crepancy between expert endorsements for treatment and the reality of treatment
unavailability frustrates substance abuse patients and their caregivers all the more,
because antiviral therapy for HCV is quite effective. Data suggest that more
than 50 percent of treated individuals will produce virus-free blood samples for
years (Fried et al., 2002; Manns et al., 2001).
Although lack of access to treatment is a glaring problem, despair appears unwar-
ranted. The natural history of HCV infection is typically more benign than many
people realize. With aggressive risk reduction, the majority of patients will remain
healthy even without treatment (Thomas et al., 2000). Moreover, an evolving body
of data suggests that those addicted individuals who do need treatment can have
successful outcomes despite multiple so-called barriers, especially if treatment takes
place in a setting that can address their special needs (Backmund et al., 2001; Edlin,
2002; Sylvestre et al., 2005).
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Addiction specialists can contribute critically to allevi-
ating the impact of the hepatitis C epidemic. The edu-
cation and lifestyle stabilization that treatment provides
are vital aids to interrupting the chain of viral trans-
mission and helping infected individuals maintain or
recover their health. This article aims to familiarize read-
ers with the fundamentals of hepatitis C so that they can
maximize their effectiveness on behalf of their patients.
THE COURSE OF HEPATITIS C
Hepatitis C is the most common blood-borne illness in
the United States (Alter, 1999; Sulkowski, 2001). More
than 4 million Americans have been exposed to the virus,
and 2.7 million are thought to be chronically infected,
making this disease four to five times more widespread
than HIV infection. Hepatitis C is the most common
reason for liver transplantation in the Nation and causes
10,000 to 12,000 deaths annually (Centers for Disease
Control and Prevention (CDC), 1998).
Because HCV transmission occurs primarily through
exposure to infected blood, injection drug use is now
responsible for the majority of new and existing cases of
hepatitis C (Alter and Moyer, 1998). Some 70 to 96 per-
cent of long-term injectors have been exposed, about
half of them during their first year of injecting (Garfein
et al., 2000). Blood-to-blood contact transmits HCV
from person to person very efficiently; thus, people can
acquire it through sharing not only needles and syringes,
but also other injection equipment, including cottons,
cookers, and rinse water (Hagan et al., 2001). Risk may
also attend sharing or reuse of:
• Cocaine-snorting paraphernalia such as straws or 
tubing, because the drug produces intranasal bleed-
ing (Conry-Cantilena et al., 1996); and
• Tattoo needles, razors, and toothbrushes used by infected
individuals.
Sexual transmission occurs in fewer than 5 percent
of stable monogamous relationships (CDC, 1998).
However, sex with multiple partners or sex when either
partner has a sexually transmitted disease raises the trans-
mission risk (CDC, 1998). Vertical transmission is
uncommon, affecting about 5 percent of children born
to infected women.
Fortunately, hepatitis C does not usually lead to sig-
nificant clinical problems during the first two decades
of infection. Although estimates vary widely accord-
ing to the population studied, overall only about 10 to
15 percent of chronically infected persons develop 
cirrhosis, with the associated risks for end-stage liver 
disease and hepatocellular carcinoma, after 20 years
(National Institutes of Health, 2002). Disease progres-
sion occurs more commonly in males, individuals
who acquired their infections at older ages, and those
with concurrent hepatitis B or conditions associated
with immunosuppression, such as HIV infection 
(Thomas et al., 2000). In addition, alcohol ingestion of
30 g/day in men or 20 g/day in women accelerates liver
damage (Poynard et al., 2001; Schiff, 1997). Interestingly,
some evidence suggests that hepatitis C may follow a
more benign course when contracted via injection drug
use, despite the potential risks of ongoing injecting 
behaviors and alcohol consumption (Wilson et al., 2006).
TEST
HCV antibody test
HCV viral assay (PCR,
TMA)
Liver biopsy
HCV genotype
TABLE 1. Tests to Diagnose and Assess Hepatitis C
WHAT IT IS
Test of prior exposure to HCV
Test that detects HCV in the
blood
Examination under a micro-
scope of a small piece of liver
removed by a needle 
Test that determines the
“strain” of HCV that you
have
WHAT IT TELLS YOU
If you were exposed to HCV
sometime in the past
If you are currently infected
with  HCV 
The amount of liver damage
and whether there are other
causes of liver inflammation
How long you need treatment
and your chances of success-
ful treatment
WHAT IT DOESN’T TELL YOU
Whether you are currently infected 
with HCV
How much your liver is damaged
Whether you need treatment
The likelihood of viral clearance on
treatment
Whether the treatment was successful
How much your liver is damaged
Whether you need treatment
Abbreviations: HCV, hepatitis C virus; PCR, polymerase chain reaction; TMA, transcription-mediated amplification. 
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DIAGNOSTIC TESTS AND THE DECISION TO
TREAT
For the majority of patients with hepatitis C, the deci-
sion about the need for treatment is based on the pres-
ence of chronic infection and an assessment of the amount
of liver damage that has occurred. The hepatitis C eval-
uation pathway usually involves three tests: an antibody-
based blood test to document prior exposure to the virus,
a viral assay to confirm active infection, and a liver biopsy
to establish the extent of liver damage (Table 1). In
patients who are actively infected, as shown by the pres-
ence of detectable virus in the blood, a liver biopsy show-
ing significant liver damage provides the best indication
that treatment is needed. A fourth test, one that deter-
mines the HCV genotype, informs the choice of antivi-
ral treatment intensity and duration.
Screening
Patients should be screened for hepatitis C if they report
any potential risk factors for infection. Screening is based
on risk status—not the presence of symptoms—because
most infected individuals experience no symptoms or
only nonspecific ones such as fatigue or muscle and joint
aches. Abnormal liver function test results are not pre-
requisites for HCV testing, because close to half of infected
patients have normal transaminase values and only about
15 percent have values that remain persistently elevated
on repeated measures (Inglesby et al., 1999). Hepatitis
C blood tests are not difficult to understand, but mis-
interpretations are fairly common and can incite undue
concern. A basic familiarity with the implications of the
different tests is key.
The screen is an antibody-mediated immunoassay.
Although this test is highly sensitive and specific, a pos-
itive finding does not establish that the individual has
HCV infection: It simply shows that he or she was exposed
to the virus at some time in the past and the body responded
by forming antibodies. About 75 percent of antibody-
positive patients are chronically infected, but the rest—
for reasons that remain unknown—have spontaneously
cleared their infections. Individuals in this lucky quar-
ter have no detectable virus in their blood and therefore
do not have hepatitis C (National Institutes of Health,
2002). Without additional exposures, they are not at
risk for suffering the consequences of the disease or trans-
mitting it to others.
HCV Viral Assay
Differentiating the antibody-positive patients who have
hepatitis C—that is, active HCV infection—from those
who have cleared the virus requires a molecular test to
detect the virus itself. These tests, such as the polymerase
chain reaction, are available as either a qualitative
(positive/negative) or a quantitative assay.
It is important to recognize that, unlike the viral load
of HIV infection, the hepatitis C viral load (i.e., the
quantity of virus present) does not correlate with dis-
ease activity. Hepatitis C viral loads in the millions of
particles per milliliter of blood are common and often
elicit concern. However, high viral loads frequently occur
in perfectly healthy individuals, and low viral loads may
be present in persons with extensive damage to the liver.
Liver Biopsy
A diagnosis of active hepatitis C does not in itself indi-
cate a need for treatment. Typically, patients require
treatment only if the disease is causing significant liver
damage or if their symptoms are severe. Because hepa-
titis C is often asymptomatic, biopsy is the most reliable
and definitive means of confirming the presence of liver
injury and quantifying its extent. Although a biopsy
should not be considered an absolute prerequisite for
the decision to treat, a finding of extensive liver damage
generally warrants treatment; patients who find out they
have only slight damage may safely delay treatment.
Apprehension over undergoing a liver biopsy is a
major hurdle for many of our patients (perhaps eclipsed
only by the financial barrier posed by lack of insurance).
In fact, though the test is reviled, it is a safe and simple
outpatient procedure, with only a 1/100,000 incidence
of serious consequences. Moreover, most patients report
only mild discomfort, and the majority of patients who
have biopsies get the good news that they do not need
treatment, at least for the present time. For the remain-
der, the information that the liver has already incurred
enough damage to require treatment can strengthen
resolve to initiate and adhere to the challenging med-
ication regimen. A variety of noninvasive tools for quan-
tifying liver damage are currently undergoing testing,
although none has yet been approved by the Food and
Drug Administration. 
HCV Genotype
There are six known HCV genotypes, and most patients
harbor only one of them. Some of the genotypes are asso-
ciated with greater responsiveness, others with greater
resistance, to HCV treatment. Accordingly, a blood test
to determine the genotype of the virus causing a patient’s
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HCV infection is the basis for selecting the duration and
dosage of HCV medication regimens.
HEPATITIS C TREATMENT BASICS
Is there a cure for hepatitis C? Based on what we now
know, the answer is, “probably.”
Approximately 55 percent of patients who complete
their prescribed course of antiviral medications have no
detectable virus in their blood 6 months later (Fried et
al., 2002; Manns et al., 2001). Long-term studies of
patients after they achieved this benchmark, called the
sustained virologic response (SVR), showed that the vast
majority remained virus-free after years of additional
followup (Lau et al., 1998; Swain et al., 2007). Therefore,
hepatologists generally concur that SVR is probably 
synonymous with cure, much as cancer relapse becomes
increasingly less likely as tumor-free years accumulate.
The belief that HCV has been eradicated when it does
not reappear in blood tests over years is strengthened by
the fact that it is an RNA-containing virus. As such, it
lacks the ability of HIV and some other viruses to hide
inside human cells by integrating itself into human
nuclear DNA. Although some researchers have reported
that viral genetic material may persist in the white blood
cells or livers of sustained responders, the clinical data
look very promising—so yes, antiviral therapy proba-
bly can cure hepatitis C.
The mainstays of hepatitis C treatment are inter-
feron and ribavirin. Interferon is a natural cytokine pro-
duced by the body in response to viral infection. When
taken in pharmacologic doses, interferon enhances the
body’s immune response to hepatitis C and may lead to
viral eradication. Interferon is now available as a long-
acting conjugate with polyethylene glycol, called 
pegylated interferon, which allows for weekly dosing 
via subcutaneous injection. Ribavirin, a nucleoside ana-
log, does not work as a monotherapy. Instead, it works
in synergy with interferon and approximately doubles
the SVR rate. Patients typically take two or three 200-
mg ribavirin pills twice daily. 
T
hree case histories from the O.A.S.I.S. clinic illustrate some of the many clinical challenges faced by addicted patients with hepati-
tis C. Although none of the patients were “ideal” treatment candidates, all three successfully completed hepatitis C treatment,
albeit with varying virologic outcomes. 
Larry’s Story
Larry, a 54-year-old Latino and Vietnam veteran with a history of impulsive violence, had abused heroin for more than 30 years and had
been incarcerated for 20 years. He was methadone-maintained and abstinent from heroin when diagnosed with hepatitis C in 1998.
Genotype testing revealed that he was infected with genotype 1, and liver biopsy discovered stage 2 fibrosis. A concurrent psychiatric
workup resulted in a diagnosis of post-traumatic stress disorder. Treatment was delayed for nearly 3 years while psychiatric medications
were adjusted. Meanwhile, Larry attended weekly hepatitis education/support meetings. He developed severe anemia with hepatitis C
treatment, but his psychiatric status remained stable. Larry had no detectable HCV at the end of a 48-week treatment regimen, but HCV
recurred 3 months later. A repeat biopsy showed stage 3 fibrosis. We are currently considering retreatment options.
Tim’s Story
Tim, a 57-year-old heroin addict and alcoholic, has been maintained on methadone for many years. “Non-A, non-B” hepatitis was diag-
nosed in the 1980s. He attended a hepatitis C meeting at his methadone clinic and became interested in treatment. He was found 
to have genotype 2 HCV and cirrhosis on liver biopsy, which motivated him to stop drinking alcohol. After attending 8 months of educa-
tion/support meetings, he underwent a successful 24-week course of hepatitis C treatment complicated by depression, which
responded to treatment with a selective serotonin reuptake inhibitor. Tim experienced a sustained virologic response and is now a peer
hepatitis C educator in his community.
Gerard’s Story
Gerard, a 55-year-old African-American, abused heroin for more than 40 years and was diagnosed with hepatitis C at a blood plasma
clinic in 1992. He began court-mandated drug treatment in 2003, was initially stabilized on methadone, and later transitioned to
buprenorphine maintenance. Gerard was found to have genotype 1 HCV, but was unable to obtain a liver biopsy owing to a lack of
insurance. He requested treatment because of his lengthy history of HCV exposure. A 48-week HCV treatment was uneventful and inef-
fective; there was no virologic response. A post-treatment liver biopsy obtained as part of a research study showed no fibrosis. Further
hepatitis C treatment is not indicated in the absence of liver damage.
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As mentioned earlier, the genotype is the primary
determinant of treatment duration and medication 
dosing:
• HCV genotype 1, found in about 75 percent of U.S.
patients, is relatively resistant and requires 48 weeks
of treatment with interferon and 1,000 to 1,200 mg
of ribavirin daily. SVR rates obtained with this geno-
type are around 40 to 45 percent.
• Most of the remaining patients have genotype 2 or 3,
both of which are much more responsive to therapy.
They generally require only 24 weeks of treatment
with interferon and 800 mg of ribavirin per day. New
data suggest that some patients may achieve satisfac-
tory outcomes with only a 12- to 14-week course of
medication (Dalgard et al., 2004; von Wagner et al.,
2005). 
• Patients who have one of the less common genotypes—
4, 5, or 6—receive regimens like that for genotype 
1 and exhibit similar SVR rates. 
Unfortunately, many patients will not achieve com-
plete virologic clearance with the current treatment reg-
imens. Even so, a sizeable fraction of these patients expe-
rience stabilization or even reversal of their liver damage
while on treatment (Poynard et al., 2001). 
There are a number of options for patients who
remain actively infected following treatment, such as
extending the duration of therapy, increasing the med-
ication dosage, or using different interferons. Patients
may also benefit from a low-dose maintenance regimen
of interferon, which preliminary studies indicate may
inhibit the progress of liver damage. Lastly, because HCV-
mediated liver damage often proceeds slowly, many
patients may reasonably wait for the new hepatitis C
treatments that are expected to improve outcomes in the
coming years. These patients can be monitored every
6 to 12 months, and their livers biopsied every 4 to 
5 years.
Medication Side Effects
Unfortunately, combination therapy with interferon
and ribavirin is very costly and has an onerous side-effect
profile (Table 2). First, it shrinks the wallet. Although
free interferon and ribavirin are readily accessible through
programs for indigent patients, the cost of $15,000 to
$25,000 per treatment course dictates careful consider-
ation of each patient’s treatment need and readiness.
Interferon causes flu-like symptoms. Although they
can be distressing, they seldom threaten patients’ com-
mitment to treatment, because they peak in the early
weeks when patients are the most motivated. The med-
ication’s more insidious neuropsychiatric symptoms,
including fatigue and insomnia, are much more likely
to wear the patient down and lead to early treatment dis-
continuation (Gish, 2004; Kim and Saab, 2005).
In addition, interferon lowers the platelet and white
blood counts, a concern particularly when the patient
is an active injector because of the risks of bleeding
and infection. Ribavirin can produce potentially severe
hemolytic anemia. To keep hemoglobin levels in a tol-
erable range while maintaining a therapeutic ribavirin
dosage, many patients take weekly—and expensive—
injections of the red blood cell promoter erythropoietin.
In susceptible patients, hepatitis C treatment can pro-
mote the development of autoimmune thyroid disease
and the exacerbation of other autoimmune conditions
such as rheumatoid arthritis, lupus, and psoriasis. Patients
TABLE 2. Managing Common Side Effects of Anti-HCV Therapy 
SIDE EFFECT
Flu-like symptoms
Nausea
Fatigue
Insomnia
Skin problems
Depression
Mania
“Brain fog”
Anemia
Neutropenia
Thrombocytopenia
Hypothyroidism
STRATEGIES
Increased water intake, acetaminophen, nonster-
oidal anti-inflammatory medications
Adjustment to ribavirin dosing schedule, H2 
blockers, promethazine
Light exercise, more water, improved sleep 
hygiene
Improved sleep hygiene, diphenhydramine, 
trazodone, amitriptyline
Emollients, increased water intake
Antidepressant medication, such as a selective
serotonin reuptake inhibitor
Mood-stabilizing agents, such as olanzapine, 
quetiapine, lithium
Increased water intake, improved sleep hygiene
Reduced ribavirin dosage, erythropoietin
Reduced interferon dosage, granulocyte colony-
stimulating factor
Reduced interferon dosage, interleukin-11
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should be monitored for signs and symptoms of these
diseases and conditions (e.g., thyroid blood tests every
12 weeks). 
Approximately one-third of patients experience 
interferon-mediated psychiatric reactions, including
severe depression, mania, and psychosis (Fontana, 2000;
Hauser, 2004). Treatment-related suicides have been
reported. In light of these risks, many clinicians under-
standably hesitate to treat patients for hepatitis C if they
have a history of psychiatric illness. This practice imposes
a major barrier to treatment access for drug abusers,
many of whom have co-occurring mental illnesses.
However, a number of small studies have demonstrated
that, with monitoring and appropriate medications,
patients with pre-existing mental illness have side-
effect profiles and treatment outcomes similar to those
who do not (Pariante et al., 1999; Van Thiel et al., 1995).
Prospects for New Medications
What about new treatments? An impressive pipeline of
less toxic HCV-specific medications, including protease
and polymerase inhibitors, is in the works. Patients who
can wait for them to become available should do so.
However, patients who need treatment now should not
delay in anticipation that miracle drugs will arrive in the
very near future. The first new medications are not
expected to be approved until 2009 or 2010 at the ear-
liest. Moreover, these drugs will probably be used in
combination with interferon, at least initially.
MANAGING HEPATITIS C IN DRUG ABUSERS
The data from large-scale clinical trials of hepatitis C
treatment, while robust, tell us little about the sorts of
outcomes HCV-infected individuals with addictive dis-
orders can anticipate. These trials routinely excluded
active drug users; most made psychiatric illness a cause
for ineligibility; and many would not even admit patients
maintained on methadone. However, a growing body
of data suggests that drug abusers, even those with mul-
tiple potential barriers, can participate successfully in
hepatitis C therapy.
In the first reported study of its kind, Backmund and
colleagues (2001) recruited 50 heroin injectors for hep-
atitis C treatment at the time of their enrollment in a
methadone detoxification program in Germany. Using
standard interferon monotherapy or interferon-ribavirin
combination therapy, the group attained an SVR of
36 percent, with no significant hepatitis C outcome dif-
ferences among those who relapsed and returned to 
treatment, those who relapsed and did not return to
treatment, and those who did not relapse. 
In another study of hepatitis C treatment in methadone-
maintained patients, Mauss and colleagues (2004) pro-
spectively treated HCV infection in 100 individuals,
half in a methadone program and half either having
no history of addiction or addicted but not using metha-
done for at least 5 years. Although those in the methadone
group were more likely to stop taking their medications
and discontinue treatment during the first 8 weeks, both
groups ended up with similar SVR rates, and no par-
ticipants in either group developed serious psychiatric
events.
Similarly, this author and colleagues (2005) at the
University of California, San Francisco, showed that in
76 methadone-maintained patients, SVR rates did not
differ significantly between the following groups:
• Those with less than 6 months of abstinence from 
opioids other than methadone (22 percent) and those
with more than 6 months of abstinence (30 percent);
and
• Those who remained abstinent (35 percent) and those
who abused drugs intermittently (21 percent).
Our analysis showed that among these methadone
patients, individuals with pre-existing psychiatric con-
ditions were less likely to attain SVR (22 percent) than
those without such a disorder (35 percent). Both groups
adhered equally to treatment; their SVR differential may
have been related to interactions with psychiatric
medications or to poorly understood endocrine fac-
tors (Sylvestre et al., 2005).
Finally, Robaeys and colleagues (2006) conducted a
retrospective multicenter cohort analysis of 406 
treatment-naïve hepatitis C patients. The researchers
found no significant differences between participants
who had histories of injection drug use and those who
did not in terms of treatment compliance (91 percent
vs. 92.3 percent) or SVR (46.6 percent vs. 34.6 percent)
when the latter comparison was adjusted for geno-
type. About one-quarter of the drug abusers in this study
were maintained on methadone, and a similar propor-
tion injected drugs while on antiviral therapy. 
Additional encouraging data indicate that, although
injection drug use can lead to HCV reinfection after
treatment, it is not likely to do so. Dalgard and colleagues
(2002) followed 27 injectors who had been treated and
attained SVR. Even though 9 returned to injecting drugs,
only 1 became reinfected during 5 years (45 person-
years) of followup. Similarly, Backmund, Meyer, and
Injection drug
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Edlin (2004) noted that only 2 of 12 injectors treated
for hepatitis C reverted to HCV-positive status in 6
months of post-treatment followup—a rate that is com-
parable to typical rates of post-treatment virologic relapse
in noninjecting patients. Although some of these cases
may have represented reinfection, the genotype in each
case was the same one that the patient had contracted
originally, suggesting relapse due to incomplete viral
clearance during treatment.
Why, given these data, does the decision to pro-
vide hepatitis C treatment to addicted patients remain
controversial? The truth is, successful treatment is pos-
sible, but it is not easy. Positive outcomes require expert-
ise in infectious diseases, addiction medicine, and psy-
chiatry—preferably in an integrated setting. Few 
physicians have such comprehensive training, and few
sites have structured their programs to integrate all these
services effectively. In addition, addicted individuals 
are more likely than others to be uninsured or underin-
sured and to have additional barriers to access, such as 
unstable housing or lack of transportation.
ROLE OF ADDICTION PROFESSIONALS
Addiction professionals belong on the forefront of efforts
to help individuals infected with HCV and to contain
the epidemic. Beyond the lifestyle stabilization that is
integral to drug abuse treatment, education is usually
the most important intervention we can provide. The
two critical areas for teaching are avoiding infection and
staying healthy if infection occurs.
Addiction professionals also are well positioned to
help patients negotiate the obstacles to care. We can assist
at-risk and infected patients in obtaining a proper diag-
nostic assessment and treatment when needed. Success
in these efforts sets the stage for an additional impor-
tant dimension of help: support for those who fear liver
biopsy and those who face the unpleasantness of med-
ication side effects.
Educate for Prevention
The first, absolutely crucial message to give drug abusers
is that all injection equipment—needles, syringes, cot-
tons, cookers, and rinse water—can pick up and trans-
mit the virus. No part of an injection outfit should ever
be shared. Offer this information to noninjecting drug
users, who risk rapid seroconversion if they begin inject-
ing, as well as to past or current injectors. Inform drug-
using and addicted patients about any programs in your
state to make sterile injecting equipment available, either
via syringe exchange programs or through direct pur-
chase at local pharmacies without a prescription.
Sexual activity is a relatively inefficient way to trans-
mit HCV. According to the CDC recommendations,
persons with hepatitis C who are in long-term, stable,
monogamous relationships do not need to use condoms,
even when one partner is infected and the other is not.
However, patients who have other sexually transmitted
diseases and multiple sexual partners, factors that increase
the risk of sexual transmission of HCV, should always
use condoms. We advise patients in these groups to adopt
the following policy: no glove, no love. 
Other hepatitis C prevention measures include cov-
ering open wounds and cleaning up spilled blood with
bleach. Razors, toothbrushes, and other items that may
acquire small amounts of blood, including the straws
and pipes used for snorting or smoking drugs, should
never be shared.
Promote Self-Care
For most patients, the consequences of hepatitis C are
much less dire than those of drug abuse, and this can be
a very useful focus of discussion. Most patients remain
healthy in spite of their infection, especially if they abstain
from alcohol and get vaccinations for hepatitis A and B.
We tell our patients: You don’t need to die of the dis-
ease. Not only that, you probably don’t even need treat-
ment, but you must take care of yourself. Above all, don’t
drink alcohol. It’s like pouring gasoline on a fire. Have
your blood tested for antibodies to hepatitis A and B,
and get vaccinated if you haven’t already been exposed.
We also urge: Find out all you can about your illness.
www.hcvu.org
Hepatitis C University, a mentoring project and educational tools for
addiction professionals who wish to address hepatitis C in their practices. 
www.oasisclinic.org
The home page of the O.A.S.I.S. clinic, with various educational
resources for patients and professionals. 
www.hcvadvocate.org
A comprehensive site with hepatitis C information for patients and 
professionals. 
www.cdc.gov/ncidod/diseases/hepatitis/C/index.htm
The primary source for information about hepatitis C epidemiology and
prevention.
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If your screening test is positive, obtain a viral assay to
find out whether you are still infected or your body has
cleared the virus. If your viral assay is positive, try to get
a biopsy to find out if your liver is being damaged. If it
is, work with your doctor, and prepare yourself for treat-
ment. If you stick with your treatment, your odds of get-
ting rid of the virus are pretty good, about 50:50. And
if the coin toss doesn’t go your way, remember that newer
and better treatments are around the corner. The goal is
to make sure you’ll still be around to check them out.
Support Access and Adherence to Hepatitis C Care
Accessing screening and care on behalf of addicted patients
with hepatitis C may take persistence. The HCV anti-
body screening test is relatively inexpensive, typically
around $10, and thus affordable for almost everyone.
The HCV viral assay is more problematic, but most
county medical clinics and hospitals will provide it.
Attempts to arrange a liver biopsy are worth the effort,
and increasingly often, interventional radiologists
who do not hesitate to treat drug abusers perform these
procedures.
Pegylated interferon and ribavirin are easily access-
ible and usually available at no cost for low-income,
uninsured patients who apply to an indigent patient 
program. Specialty physicians may be encouraged to
treat an addicted person if an addiction professional
agrees to assist with patient monitoring and compliance.
Many infectious disease physicians have experience treat-
ing addicted patients with HIV, which makes them very
capable clinical managers for addicted patients with 
hepatitis C.
Even though addiction care providers do not assume
primary responsibility for hepatitis C treatment, they
can contribute immensely to successful outcomes by
providing support and helping to observe and manage
side effects. We can learn to alleviate side effects such as
nausea, insomnia, and flu-like symptoms—all of which
are minor in themselves, but any of which can lead to
treatment discontinuation if neglected. Addressing seri-
ous side effects, such as ribavirin-induced hemolytic ane-
mia or neutropenia from interferon, may fall outside
most addiction specialists’ scope of practice, but we can
still help with monitoring for problematic or potentially
worrisome symptoms, such as worsening shortness of
breath. Addiction care providers may also be better able
than consulting hepatologists to spot early signs of depres-
sion or mania, which develops in about one-third of
patients taking interferon. Early awareness of these prob-
lems maintains treatment outcomes by permitting prompt
stabilization.
Finally, every patient confronting the challenges of
hepatitis C treatment needs to hear messages of hope.
This is doubly true for our more marginalized and needy
patients who do not have a circle of supportive friends
and family. Regular moral support from within the struc-
ture of an addiction treatment program can go a long
way toward helping our patients stay the course of treat-
ment and reap the best possible results. 
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